The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

##STR00001##

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Novel 2,2′-diamino biaryls of formula (I), (II) and (III), wherein R1-R10, R1′-R10′, X1-X3 and X1-X3′ are defined in claim 1. The invention also relates to an electrochemical method for the production thereof.

Novel 2,2′-diamino biaryls of formula (I), (II) and (III), wherein R1-R10, R1′-R10′, X1-X3 and X1-X3′ are defined in claim 1. The invention also relates to an electrochemical method for the production thereof.

Inhibitors of beta lactamases and their use in treating bacterial infections are disclosed.